Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCB1 Genotype-dependent Antidepressant Dosing
NCT02237937Phase 4Unknown
- Sponsor
- HMNC Brain Health
- Start
- Sep 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of paroxetine, sertraline, citalopram, venlafaxine, amitriptyline and 4 more in major depressive disorder (MDD) (2 arms), sponsored by HMNC Brain Health. Primary endpoint: 25% improvement in the HAM-D at 28 days. Status: unknown.
02
Drugs
paroxetinesertralinecitalopramvenlafaxineamitriptyline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02237937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237937.